MTOR and breast cancer: To further determine the combinational effects of these inhibitors on breast cancer cell conversion, we found that using mTOR–ROCK inhibitors (Rapamycin/Y27632) converted breast cancer cells into iPLs with ~90% efficacy after 7 days of induction (Fig. 1b).